[go: up one dir, main page]

WO2019078634A3 - Pharmaceutical composition for prevention or treatment of insulin resistance or fatty liver, comprising ptp4a1 protein - Google Patents

Pharmaceutical composition for prevention or treatment of insulin resistance or fatty liver, comprising ptp4a1 protein Download PDF

Info

Publication number
WO2019078634A3
WO2019078634A3 PCT/KR2018/012322 KR2018012322W WO2019078634A3 WO 2019078634 A3 WO2019078634 A3 WO 2019078634A3 KR 2018012322 W KR2018012322 W KR 2018012322W WO 2019078634 A3 WO2019078634 A3 WO 2019078634A3
Authority
WO
WIPO (PCT)
Prior art keywords
insulin resistance
fatty liver
prevention
treatment
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/012322
Other languages
French (fr)
Korean (ko)
Other versions
WO2019078634A2 (en
Inventor
민정기
박종길
황병태
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Bioscience and Biotechnology KRIBB
Original Assignee
Korea Research Institute of Bioscience and Biotechnology KRIBB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Research Institute of Bioscience and Biotechnology KRIBB filed Critical Korea Research Institute of Bioscience and Biotechnology KRIBB
Publication of WO2019078634A2 publication Critical patent/WO2019078634A2/en
Publication of WO2019078634A3 publication Critical patent/WO2019078634A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to a pharmaceutical composition for prevention or treatment of insulin resistance or fatty liver, comprising a PTP4A1 protein or a polynucleotide coding for the PTP4A1 protein. Overexpression of PTP4A1 protein results in the effect of alleviating insulin resistance and suppressing fatty liver production so that the PTP4A1 protein of the present invention can be effectively used as a therapeutic agent in the metabolic syndrome field.
PCT/KR2018/012322 2017-10-18 2018-10-18 Pharmaceutical composition for prevention or treatment of insulin resistance or fatty liver, comprising ptp4a1 protein Ceased WO2019078634A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170135408A KR102496229B1 (en) 2017-10-18 2017-10-18 Pharmaceutical Composition Comprising PTP4A1 Protein for Prevention or Treatment Insulin Resistance or Non-alcoholic Fatty liver
KR10-2017-0135408 2017-10-18

Publications (2)

Publication Number Publication Date
WO2019078634A2 WO2019078634A2 (en) 2019-04-25
WO2019078634A3 true WO2019078634A3 (en) 2019-06-20

Family

ID=66174150

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/012322 Ceased WO2019078634A2 (en) 2017-10-18 2018-10-18 Pharmaceutical composition for prevention or treatment of insulin resistance or fatty liver, comprising ptp4a1 protein

Country Status (2)

Country Link
KR (1) KR102496229B1 (en)
WO (1) WO2019078634A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102216646B1 (en) * 2018-11-23 2021-02-17 차의과학대학교 산학협력단 A composition comprising mesenchymal stem cell for inhibiting adipogenesis
KR20240177783A (en) * 2023-06-19 2024-12-30 (주) 플라바이오로직스 Method for producing mesenchymal stem cells using peptides and pharmaceutical composition for treatment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258692A1 (en) * 2002-10-31 2006-11-16 Mark Pines Quinazolinone compositions for regulation of gene expression related to pathological processes
WO2010040571A2 (en) * 2008-10-10 2010-04-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
KR20160000041A (en) * 2014-06-23 2016-01-04 주식회사 바이오포트코리아 Composition comprising ginseng berry extract for preventing or treating diabetic and diabetic complication
KR20160084528A (en) * 2015-01-05 2016-07-14 서울대학교산학협력단 A protein biomarker for early diagnosis of type 2 diabetes mellitus

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10765128B2 (en) 2015-08-19 2020-09-08 Korea Research Institute Of Bioscience And Biotechnology Composition for prevention or treatment of metabolic syndrome or for antioxidation containing black bean leaf extracts and flavonol glysosides isolated therefrom as active ingredients

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258692A1 (en) * 2002-10-31 2006-11-16 Mark Pines Quinazolinone compositions for regulation of gene expression related to pathological processes
WO2010040571A2 (en) * 2008-10-10 2010-04-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
KR20160000041A (en) * 2014-06-23 2016-01-04 주식회사 바이오포트코리아 Composition comprising ginseng berry extract for preventing or treating diabetic and diabetic complication
KR20160084528A (en) * 2015-01-05 2016-07-14 서울대학교산학협력단 A protein biomarker for early diagnosis of type 2 diabetes mellitus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HWANG, BYUNG TAE: "The Multifunctional Roles of PTP4A1 in Angiogenesis and Insulin Resistance", UNIV. OF SCIENCE AND TECHNOLOGY, LIFE SCIENCE BIOMOLECULE SCIENCE, August 2017 (2017-08-01), pages 47, 50, 51, 67 *

Also Published As

Publication number Publication date
WO2019078634A2 (en) 2019-04-25
KR20190043397A (en) 2019-04-26
KR102496229B1 (en) 2023-02-06

Similar Documents

Publication Publication Date Title
PH12020500352A1 (en) Therapeutic uses of empagliflozin
PH12018501969A1 (en) Pharmaceutical composition comprising empagliflozin and uses thereof
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
EP3111931A4 (en) Pharmaceutical composition for cancer treatment containing gossypol and phenformin as active ingredients
MY187540A (en) Compounds active towards bromodomains
MX2020013740A (en) Therapeutic uses of empagliflozin.
MX2015015518A (en) Methods and compositions for the treatment of cancer.
WO2014190163A3 (en) Combination therapy for mds
MX2015016741A (en) Dual selective pi3 delta and gamma kinase inhibitors.
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
AU2016298962A8 (en) Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
MX2020002585A (en) Hdac inhibitor in combination with immune checkpoint modulator for cancer therapy.
MX2015000485A (en) Treatment of multiple sclerosis with combination of laquinimod and fampridine.
PH12017501120A1 (en) Crosslinked polydiallymine copolymers for the treatment of type 2 diabetes
HK1216300A1 (en) Pyrazolyl-based carboxamides i as crac channel inhibitors
WO2016178510A3 (en) Pharmaceutical composition for preventing or treating gleevec-resistant leukemia, containing, as active ingredient, ginsenoside f1 or rg3
WO2019078634A3 (en) Pharmaceutical composition for prevention or treatment of insulin resistance or fatty liver, comprising ptp4a1 protein
EP3277269A4 (en) Methods for prevention and treatment of cardiometabolic syndrome and compositions used therein
MX2016012127A (en) Ostreolysin, functionally related variant thereof, extract comprising ostreolysin and uses thereof.
HK1216301A1 (en) Pyrazolyl-based carboxamides ii as crac channel inhibitors
WO2020022975A3 (en) New pharmaceutical compositions in the treatment of copd
EP3881845A3 (en) Combination of trazodone and gabapentin for the treatment of pain
MX2016001177A (en) Treatment of multiple sclerosis with combination of laquinimod and flupirtine.
IN2013MU03428A (en)
MX2023005681A (en) Pharmaceutical composition for treating acute and chronic pain, containing polmacoxib and tramadol.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18868993

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18868993

Country of ref document: EP

Kind code of ref document: A2